Project Grant K22CA297064
Award Date 9/1/25
Completion Date 8/31/28
Dollars Obligated $193K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Virginia, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $415,257 to the University of Virginia to conduct research aimed at identifying epigenetic and transcriptomic drivers of racial disparities in colorectal cancer risk and site-specific tumor development. The key products and services to be delivered under this 2-year award include: Identifying site-specific DNA methylation-associated gene expression signatures across different...
- This $399,187 federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support research at Virginia Commonwealth University to study the role of ATG16L1 isoforms in colorectal cancer health disparities. The key objectives are to: 1) Determine whether the ATG16L1 T300T isoform, which is more predominant in African Americans, promotes more aggressive colorectal tumor growth and metastasis compared to the A300A isoform found more in...
- This $4,174,595 Project Grant awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research led by Vanderbilt University Medical Center to leverage omics and electronic health records data to study the genetics of colorectal adenomas (precancerous lesions) and explore drug repurposing for colorectal cancer prevention. The key objectives are to conduct genome-wide association studies, methylome-wide association studies, transcriptome-wide...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) provides $154,642 to the Sloan-Kettering Institute for Cancer Research in New York to conduct research on identifying conserved cancer-specific immunopeptide targets in metastatic colorectal cancer. The project aims to systematically elucidate the evolving immunopeptidome (peptides presented by HLA class I molecules) from patient-derived colorectal cancer organoids to reveal targetable...
- This $248,998 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research by The General Hospital Corporation (Massachusetts General Hospital) to identify gut microbial and metabolomic biomarkers that link the consumption of ultra-processed foods to colorectal cancer risk. The research will leverage multi-omics data from large prospective cohorts and integrate a medically tailored meal intervention into the oncology care of colorectal...
- This federal Project Grant award of $133,598 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) supports research by The Leland Stanford Junior University (Stanford University) to utilize a biobank of patient-derived premalignant colon organoid samples to investigate new chemoprevention strategies for familial adenomatous polyposis (FAP). The project aims to better understand how signaling and metabolic pathways are altered in premalignant polyps in order to...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $406,611 to the University of Texas Health Science Center at Houston (UTHealth) to identify the role and signaling mechanisms of the GPR56 protein in colorectal cancer progression and therapy resistance. The project aims to develop and evaluate novel antibody-drug conjugates and combination therapies targeting GPR56 for the improved treatment of colorectal cancer. Key activities...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will support the development of a "Spatial Profiling-Based Immune Hub Perturbation Platform" to improve immunotherapy for colorectal cancer. The $710,361 award to J. David Gladstone Institutes will fund research to create a novel experimental framework to systematically test and prioritize candidate genes and therapies based on their ability to induce effective anti-tumor immune hubs -...
- This federal Project Grant award of $205,700 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research at the Sloan-Kettering Institute for Cancer Research in New York aimed at understanding and overcoming rapid resistance to targeted therapies in colorectal cancer. The key objectives are to evaluate how intrinsic tumor features modulate the development of resistance to targeted therapies, and to test a novel combination approach to...
- This $2,864,671 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Regents of the University of Michigan is focused on developing a novel strategy to enzymatically inhibit colibactin, a procarcinogenic metabolite from enteric bacteria associated with colorectal cancer (CRC). The objectives are to: (1) create engineered microbes that can deliver the colibactin inactivation protein ClbS to safely and effectively neutralize colibactin in the gut,...